Valuation: PYC Therapeutics Limited

Market Cap 2.15B 1.52B 1.32B 1.24B 1.13B 2.12B 145B 14.55B 5.69B 72.78B 5.72B 5.6B 243B P/E 2026 *
-30.3x
P/E 2027 * -23.8x
Enterprise Value 1.49B 1.05B 913M 856M 780M 1.47B 101B 10.06B 3.93B 50.33B 3.96B 3.87B 168B EV / Sales 2026 *
406x
EV / Sales 2027 * -
Free-Float
70.64%
Yield 2026 *
-
Yield 2027 * -
1 day-1.83%
1 week+0.94%
Current month+26.47%
1 month+38.71%
3 months+49.31%
6 months+41.91%
Current year+29.91%
1 week 1.98
Extreme 1.98
2.23
1 month 1.52
Extreme 1.515
2.23
Current year 1.04
Extreme 1.045
2.23
1 year 0.85
Extreme 0.847
2.23
3 years 0.52
Extreme 0.52
2.23
5 years 0.5
Extreme 0.5
2.23
10 years 0.14
Extreme 0.14
2.23
Manager TitleAgeSince
Chief Executive Officer 42 19/08/2020
Director of Finance/CFO 47 07/07/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 30/11/2018
Director/Board Member - 22/09/2025
Chairman 66 18/11/2025
Date Insider Type Main position Quantity % Market Cap.
23/12/25 Free

Chairman

2,000,000 0.3429%
26/11/25 Buy

Chief Executive Officer

133,350 0.0229%
27/2/25
Australia Land Pty Ltd.
BuyCompany 28,000,000 6.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-1.83%+0.94%+59.26%+298.15% 1.52B
+0.76%+0.56%+3.49%+15.30% 48.72B
-0.14%+4.03%+482.13%+584.43% 43.99B
-0.06%+9.62%+24.63%+81.63% 40.82B
-0.87%+2.40%+30.01%+9.95% 39.79B
-4.04%+6.15%+23.03%+48.00% 32.7B
-1.41%+1.57%+29.98%+123.68% 16.66B
+0.35%+4.61% - - 16.84B
+0.86%+0.46%+5.09%+21.75% 13.95B
+0.84%+9.07%+86.17%+32.60% 13.58B
Average -0.55%+3.99%+82.64%+135.05% 26.86B
Weighted average by Cap. -0.50%+3.93%+103.94%+139.10%

Financials

2026 *2027 *
Net sales 3.67M 2.59M 2.25M 2.11M 1.92M 3.61M 247M 24.77M 9.68M 124M 9.74M 9.53M 413M -
Net income -57.43M -40.63M -35.21M -32.99M -30.09M -56.56M -3.88B -388M -152M -1.94B -153M -149M -6.47B -85.75M -60.67M -52.56M -49.25M -44.92M -84.45M -5.79B -579M -226M -2.9B -228M -223M -9.66B
Net Debt -664M -470M -407M -382M -348M -654M -44.83B -4.49B -1.75B -22.44B -1.76B -1.73B -74.84B -579M -409M -355M -332M -303M -570M -39.06B -3.91B -1.53B -19.56B -1.54B -1.5B -65.21B
Logo PYC Therapeutics Limited
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002).
Employees
5
Date Price Change Volume
13/08/26 $2.150 -1.83% 1,869,473
12/08/26 $2.190 +2.34% 1,220,227
11/08/26 $2.140 +2.39% 2,223,443
10/08/26 $2.090 +2.45% 1,174,447
07/08/26 $2.040 -4.23% 1,410,956
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.190AUD
Average target price
3.752AUD
Spread / Average Target
+71.32%

Quarterly revenue - Rate of surprise